Wysa vs Tempus

Tempus has a disclosed valuation of $8.1B, while Wysa's valuation is not publicly available, making a direct size comparison difficult. Tempus employs 2500 people.

Tempus has raised more in total funding at $1.3B, compared to Wysa's $30M — a gap of $1.3B. Combined, the two companies have completed 5 known funding rounds.

Tempus holds the higher Awaira Score at 84/100, compared to Wysa's 63/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 21-point gap that reflects meaningful differences in scale or traction.

Wysa was founded by Jo Aggarwal in 2015. Tempus was founded by Eric Lefkofsky in 2015. Visit each company's profile on Awaira for a full founder biography.

Wysa: Wysa is an AI mental health platform that provides evidence-based cognitive behavioral therapy techniques through a conversational AI chatbot, offering anonymous, stigma-free mental health support accessible via smartphone at any hour. The platform uses clinically validated CBT, DBT, and mindfulness exercises delivered conversationally, and provides a step-up pathway to licensed human therapists for users requiring more intensive support.\n\nThe company raised approximately $30M in Series B funding and has deployed its platform to over five million users globally, including through enterprise employee wellness programs, NHS partnerships in the UK, and healthcare system integrations in the United States and India. Wysa has published peer-reviewed clinical evidence demonstrating statistically significant improvements in depression and anxiety scores.\n\nMental health care access is a global crisis with a severe therapist shortage that AI can meaningfully address at the first-line support level. Wysa's combination of clinical validation, enterprise and payer relationships, and scalable AI delivery model positions it as one of the more credible players in the crowded digital mental health space. Tempus: Tempus is an AI-driven oncology and precision medicine company founded in 2015 that leverages machine learning and data analysis to improve cancer treatment outcomes. The platform aggregates and analyzes vast datasets including clinical data, imaging, molecular information, and outcomes to identify personalized treatment strategies for cancer patients. Tempus's core technology uses artificial intelligence to match patient-specific tumor characteristics with optimal therapeutic options, enabling oncologists to make data-informed treatment decisions. The company operates primarily in the United States and serves hospitals, health systems, and oncology practices through its cloud-based platform. Its applications span multiple cancer types including lung, colorectal, breast, and ovarian cancers. Tempus has secured $1.3 billion in total funding and achieved a valuation of $8.1 billion, reflecting significant investor confidence in precision oncology. The company went public, transitioning from private to public markets. Tempus competes with other AI health platforms and precision medicine companies like Foundation Medicine and others focused on genomic analysis and treatment selection. The company's growth trajectory reflects expanding adoption of AI-driven oncology tools and increasing demand for personalized cancer treatment protocols. Its competitive positioning centers on its data infrastructure scale and machine learning capabilities applied to complex clinical decision-making. Tempus combines clinical, imaging, and molecular data through AI to provide real-time oncology treatment recommendations at scale across U.S. health systems.

Both Wysa and Tempus were founded in the same year — 2015. Despite sharing a founding year, they may have launched at different times within that year, which can matter in fast-moving AI markets.

Wysa has approximately 50-200 employees, while Tempus has approximately 2500. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Wysa and Tempus are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.